Immunoglobulin/T-Cell Receptor Gene Rearrangement Analysis Using RNA-Seq.

Acute lymphoblastic leukemia Gene rearrangements Immunoglobulin Marker identification Minimal residual disease RNA-Seq T-cell receptor Whole exome sequencing Whole genome sequencing

Journal

Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969

Informations de publication

Date de publication:
2022
Historique:
entrez: 27 5 2022
pubmed: 28 5 2022
medline: 1 6 2022
Statut: ppublish

Résumé

Identification of immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements in acute lymphoblastic leukemia (ALL) patients at initial presentation are crucial for monitoring of minimal residual disease (MRD) during subsequent follow-up and thereby for appropriate risk-group stratification. Here we describe how RNA-Seq data can be generated and subsequently analyzed with ARResT/Interrogate to identify possible MRD markers. In addition to the procedures, possible pitfalls will be discussed. Similar strategies can be employed for other lymphoid malignancies, such as lymphoma and myeloma.

Identifiants

pubmed: 35622320
doi: 10.1007/978-1-0716-2115-8_4
pmc: PMC9761498
doi:

Substances chimiques

Immunoglobulins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

61-77

Informations de copyright

© 2022. The Author(s).

Références

Leukemia. 2019 Sep;33(9):2241-2253
pubmed: 31243313
Leukemia. 2019 Sep;33(9):2254-2265
pubmed: 31227779
Leukemia. 2007 Apr;21(4):706-13
pubmed: 17287857
Leukemia. 2019 Aug;33(8):1895-1909
pubmed: 30842609
Leukemia. 2019 Sep;33(9):2227-2240
pubmed: 31197258
Leukemia. 2020 Sep;34(9):2418-2429
pubmed: 32099036
Blood. 2015 Jun 25;125(26):3996-4009
pubmed: 25999452
Leukemia. 2008 Apr;22(4):771-82
pubmed: 18239620
Bioinformatics. 2017 Feb 1;33(3):435-437
pubmed: 28172348
Blood. 2020 Aug 27;136(9):1108-1111
pubmed: 32609826
Nat Commun. 2020 Jul 7;11(1):3390
pubmed: 32636395
Leukemia. 2007 Apr;21(4):604-11
pubmed: 17287850
Leukemia. 2021 Mar;35(3):924-928
pubmed: 33608635
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
Methods Mol Biol. 2009;538:115-50
pubmed: 19277574
J Clin Oncol. 2021 Feb 20;39(6):652-662
pubmed: 33405950
J Clin Oncol. 2016 Aug 1;34(22):2591-601
pubmed: 27269950
Blood. 2020 Aug 27;136(9):1105-1107
pubmed: 32438392
BMC Mol Biol. 2006 Jan 31;7:3
pubmed: 16448564

Auteurs

Vincent H J van der Velden (VHJ)

Department of Immunology, Laboratory Medical Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. v.h.j.vandervelden@erasmusmc.nl.

Lorenz Bastian (L)

Department of Hematology, University of Schleswig-Holstein, Kiel, Germany.

Monika Brüggemann (M)

Department of Hematology, University of Schleswig-Holstein, Kiel, Germany.

Alina M Hartmann (AM)

Department of Hematology, University of Schleswig-Holstein, Kiel, Germany.

Nikos Darzentas (N)

Department of Hematology, University of Schleswig-Holstein, Kiel, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH